Parrondo Ricardo D, Ailawadhi Sikander, Sher Taimur, Chanan-Khan Asher A, Roy Vivek
Mayo Clinic, Jacksonville, FL.
JCO Oncol Pract. 2020 Feb;16(2):56-66. doi: 10.1200/JOP.19.00335.
Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.
尽管在过去十年中用于治疗多发性骨髓瘤（MM）的治疗手段不断发展，但自体干细胞移植（ASCT）仍然是新诊断和复发MM患者治疗中不可或缺的一部分。新型疗法的出现，如免疫调节剂、蛋白酶体抑制剂和单克隆抗体，已带来了前所未有的深度血液学缓解水平。尽管如此，研究表明ASCT具有累加效应，可导致缓解进一步加深。随着MM治疗药物的不断发展，了解它们与ASCT联合使用的时机、持续时间和顺序对于使MM患者获得最深缓解和生存益处至关重要。本综述旨在讨论ASCT在MM管理中的作用，特别关注ASCT在新型疗法和微小残留病背景下的作用。
